{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:26:47Z","timestamp":1771064807703,"version":"3.50.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1513\/annalsats.202005-574rl","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T17:33:42Z","timestamp":1599845622000},"page":"1639-1642","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":4,"title":["Estimated Population-Level Impact of Using a Six-Week Regimen of Daily Rifapentine to Treat Latent Tuberculosis Infection in the United States"],"prefix":"10.1093","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6106-6834","authenticated-orcid":false,"given":"Sourya","family":"Shrestha","sequence":"first","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Parriott","sequence":"additional","affiliation":[{"name":"University of California San Francisco San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas A.","family":"Menzies","sequence":"additional","affiliation":[{"name":"Harvard T.H. Chan School of Public Health Boston, Massachusetts and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0279-8170","authenticated-orcid":false,"given":"Priya B.","family":"Shete","sequence":"additional","affiliation":[{"name":"University of California San Francisco San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew N.","family":"Hill","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne M.","family":"Marks","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Dowdy","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,1]]},"reference":[{"key":"2026012203452638900_bib1","article-title":"Reported tuberculosis in the United States, 2018","author":"Centers for Disease Control and Prevention (CDC)","year":"2019"},{"key":"2026012203452638900_bib2","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3201\/eid2410.180716","article-title":"Simple estimates for local prevalence of latent tuberculosis infection, United States, 2011-2015","volume":"24","author":"Haddad","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2026012203452638900_bib3","doi-asserted-by":"crossref","first-page":"e0140881","DOI":"10.1371\/journal.pone.0140881","article-title":"Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011-2012","volume":"10","author":"Miramontes","year":"2015","journal-title":"PLoS One"},{"key":"2026012203452638900_bib4","article-title":"Division of tuberculosis elimination strategic plan 2016\u20132020","author":"Centers for Disease Control and Prevention (CDC)","year":"2018"},{"key":"2026012203452638900_bib5","first-page":"28","article-title":"Controlled chemoprophylaxis trial in tuberculosis: a general review","volume":"17","author":"Ferebee","year":"1970","journal-title":"Adv Tuberc Res"},{"key":"2026012203452638900_bib6","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis","year":"1982","journal-title":"Bull World Health Organ"},{"key":"2026012203452638900_bib7","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012203452638900_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2026012203452638900_bib9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"key":"2026012203452638900_bib10","article-title":"Assessment of the safety, tolerability, and effectiveness of rifapentine given daily for LTBI (ASTERoiD)","author":"NIH","year":"2018"},{"key":"2026012203452638900_bib11","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/aje\/kwy094","article-title":"Prospects for tuberculosis elimination in the United States: results of a transmission dynamic model","volume":"187","author":"Menzies","year":"2018","journal-title":"Am J Epidemiol"},{"key":"2026012203452638900_bib12","doi-asserted-by":"crossref","first-page":"e0214532","DOI":"10.1371\/journal.pone.0214532","article-title":"Outlook for tuberculosis elimination in California: an individual-based stochastic model","volume":"14","author":"Goodell","year":"2019","journal-title":"PLoS One"},{"key":"2026012203452638900_bib13","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/aje\/kwz147","article-title":"Impact and effectiveness of state-level tuberculosis interventions in California, Florida, New York, and Texas: a model-based analysis","volume":"188","author":"Shrestha","year":"2019","journal-title":"Am J Epidemiol"},{"key":"2026012203452638900_bib14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012203452638900_bib15","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201907-1289OC","article-title":"Comparative modeling of tuberculosis epidemiology and policy outcomes in California","volume":"201","author":"Menzies","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203452638900_bib16","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.5588\/ijtld.13.0423","article-title":"Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States","volume":"17","author":"Shepardson","year":"2013","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/17\/12\/1639\/66347997\/annalsats_17_12_1639.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/17\/12\/1639\/66347997\/annalsats_17_12_1639.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:50:54Z","timestamp":1769071854000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/17\/12\/1639\/8418668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,1]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202005-574rl","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2020-12-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}